Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 1;66(1):22-35.
doi: 10.1097/GRF.0000000000000765. Epub 2022 Nov 21.

Enrollment of Racial and Ethnic Minoritized Groups in Gynecologic Oncology Clinical Trials: A Review of the Scope of the Problem, Contributing Factors, and Strategies to Improve Inclusion

Danika Barry  1 , Jecca R Steinberg  1 , Mary Towner  1   2 , Emma L Barber  1   2   3 , Melissa A Simon  1   3 , Dario R Roque  1   2   3
Affiliations
Review

Enrollment of Racial and Ethnic Minoritized Groups in Gynecologic Oncology Clinical Trials: A Review of the Scope of the Problem, Contributing Factors, and Strategies to Improve Inclusion

Danika Barry et al. Clin Obstet Gynecol. .

Abstract

Racial inequities are well-documented across the gynecologic oncology care continuum, including the representation of racial and ethnic minoritized groups (REMGs) in gynecologic oncology clinical trials. We specifically reviewed the scope of REMG disparities, contributing factors, and strategies to improve inclusion. We found systematic and progressively worsening under-enrollment of REMGs, particularly of Black and Latinx populations. In addition, race/ethnicity data reporting is poor, yet a prerequisite for accountability to recruitment goals. Trial participation barriers are multifactorial, and successful remediation likely requires multi-level strategies. More rigorous, transparent data on trial participants and effectiveness studies on REMG recruitment strategies are needed to improve enrollment.

PubMed Disclaimer

Conflict of interest statement

D.R.R.: Speakers Bureau: GSK, Myriad; Consultant: Myriad, Intuitive. The remaining authors declare no conflicts of interest.

Figures

Figure 1.
Figure 1.
Three-year trend of underrepresented minority (URM) representation of Gyn Onc vs. Ob Gyn vs. All Other Surgical vs. All Other Medical specialties. From Ngo NT, Aniagolu N, Lang J, Mcdougale A, Ekwenna O. Underrepresented minority representation trends in gynecologic oncology fellowships in the United States. Gynecologic Oncology. 2021;160(2):485–491; with permission (See Figure 1 in original).
See this image and copyright information in PMC

References

    1. DeSantis CE, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Cancer statistics for African Americans, 2019. CA Cancer J Clin. 2019;69(3):211–233. doi:10.3322/caac.21555 - DOI - PubMed
    1. Del Carmen MG, Rice LW. Towards the elimination of health care disparities in gynecologic oncology: Call to action. Gynecol Oncol. 2018;149(1):1–3. doi:10.1016/j.ygyno.2017.12.012 - DOI - PubMed
    1. Doll KM. Investigating Black-White disparities in gynecologic oncology: Theories, conceptual models, and applications. Gynecol Oncol. 2018;149(1):78–83. doi:10.1016/j.ygyno.2017.10.002 - DOI - PubMed
    1. Grette KV, White AL, Awad EK, et al. Not immune to inequity: minority underrepresentation in immunotherapy trials for breast and gynecologic cancers. Int J Gynecol Cancer. 2021;31(11):1403–1407. doi:10.1136/ijgc-2021-002557 - DOI - PubMed
    1. National Institutes of Health Revitalization Act; 1993. Accessed May 26, 2022. https://orwh.od.nih.gov/sites/orwh/files/docs/NIH-Revitalization-Act-199...

Publication types